Hydralazine-induced pulmonary-renal syndrome: a case report

Drug-induced lupus erythematosus differs in its manifestation from drug-induced vasculitis. The former is associated with characteristic symptoms that improve following discontinuation, whereas the latter is predominantly an antineutrophil cytoplasmic antibody (ANCA) positive small vessel vasculitis...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of therapeutics Vol. 19; no. 4; pp. e136 - e138
Main Authors:	Kalra, Ankur, Yokogawa, Naoto, Raja, Haroon, Palaniswamy, Chandrasekar, Desai, Priyank, Zanotti-Cavazzoni, Sergio L, Rajaram, Sri-Sujanthy
Format:	Journal Article
Language:	English
Published:	United States 01-07-2012
Subjects:	Aged Female Glomerulonephritis - chemically induced Glomerulonephritis - physiopathology Glucocorticoids - therapeutic use Hemorrhage - chemically induced Hemorrhage - physiopathology Humans Hydralazine - adverse effects Hydralazine - therapeutic use Immunosuppressive Agents - therapeutic use Lung Diseases - chemically induced Lung Diseases - physiopathology Vasodilator Agents - adverse effects Vasodilator Agents - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Drug-induced lupus erythematosus differs in its manifestation from drug-induced vasculitis. The former is associated with characteristic symptoms that improve following discontinuation, whereas the latter is predominantly an antineutrophil cytoplasmic antibody (ANCA) positive small vessel vasculitis involving the kidneys, skin, and lungs. We present a case of advanced disease in an elderly Caucasian woman requiring corticosteroids, and immunosuppressive therapy, who was on hydralazine for >2 years.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1075-2765 1536-3686
DOI:	10.1097/MJT.0b013e3181ed838c